Numinus Wellness (NUMI) Investor presentation summary

Market opportunity and industry trends

• Global mental health market projected to grow from $380B in 2020 to $538B by 2030, driven by rising rates of mental illness and addiction.

• One in four Canadians and about 32% of American adults reported symptoms of depression, anxiety, or PTSD in recent years.

• Over 107,000 overdose deaths reported in the U.S. in 2023, highlighting urgent mental health needs.

• Psychedelic medicines, such as Spravato, are gaining momentum, with FDA approval for MDMA-assisted PTSD therapy expected as early as 2024-2025.

• Short-acting psychedelics and teletherapy models are emerging, increasing demand for research and practitioner training.

Business model and strategic positioning

• Integrated model combines practitioner training and clinical research, serving both professionals and drug developers.

• Streamlined operations and reorganization have aligned revenue with overhead, positioning for growth.

• Transitioned out of U.S.-based clinical operations, focusing on research and training.

• Accredited training programs in Colorado and Oregon, with expanding curriculum and experiential learning.

• Strategic growth channels include partnerships with research institutions and alumni networks.

Clinical research and partnerships

• Cedar Clinical Research managed 18 clinical trials in Q4 FY24, facilitating 306 patient appointments.

• Research clients include leading biotech, non-profits, and academic institutions such as MAPS, MindMed, and Merck.

• Capabilities span phase I-IV trials, patient recruitment, and data management for psychedelic and mental health studies.